Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): The Biggest Winners of the FDA’s Breakthrough Designation

The other big winner here, which came as a big surprise to me, is Novartis AG (ADR) (NYSE:NVS). To start with, Novartis has two drugs – LDK378 and serelaxin – with the breakthrough therapy designation. LDK378 demonstrated an incredible overall response rate of 60% in a 78-patient mid-stage study for ALK+ non-small cell lung cancer and should serve as enough of a basis to file for an NDA in early 2014. Serelaxin is equally exciting with the drug reducing mortality rates in a late-stage trial by 37%. If approved, it would become the first new acute heart failure drug to come to market in more than two decades.

But, Novartis AG (ADR) (NYSE:NVS) is also a crucial component to Pfizer Inc. (NYSE:PFE)’s breast cancer drug palbociclib which has been touted as a potential $5 billion per year drug. The reason is that Novartis’ Femara is given in conjunction with palbociclib to produce its desired results. In a mid-stage metastatic breast cancer trial, those patients given just Femara demonstrated 7.5 months of progression-free survival compared to the combination of palbociclib and Femara which delivered a whopping PFS of 26.1 months!

Adding these together — peak sales estimates of $5 billion for palbociclib, anywhere from $1.5 billion to $6 billion for serelaxin, and no published estimates for LDK378 (but I’d venture a guess of around $2 billion) — and you’ll see that Novartis AG (ADR) (NYSE:NVS) offers one of the most intriguing pipelines right now among the companies which have received the breakthrough designation for one of their drugs.

This is working

The breakthrough designation isn’t handed out lightly by the FDA as you can see, but it also can help us identify biopharmaceutical companies which are likely to show long-term gains. Let’s just say that if I was a shareholder Johnson & Johnson (NYSE:JNJ) or Novartis AG (ADR) (NYSE:NVS) right now, I’d be very pleased with the expedited review process that the breakthrough designation offers.

The article These 2 Companies Are the Biggest Winners of the FDA’s Breakthrough Designation originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of, and recommends Johnson & Johnson. It also recommends Vertex Pharmaceuticals. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.